Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Iu A Iuricheva"'
Autor:
E B Maĭkov, Iu A Iuricheva, N Iu Mironov, S F Sokolov, S P Golitsyn, L V Rozenshtraukh, E I Chazov
Publikováno v:
Терапевтический архив, Vol 87, Iss 1, Pp 38-48 (2015)
Aim. To evaluate the efficacy and safety of refralon (niferidil), a new class III antiarrhythmic agent whose activity is related to the block of delayed rectifying potassium current and to the prolongation of atrial and ventricular action potential a
Externí odkaz:
https://doaj.org/article/a061fcf2ee1442eebc93d2a1c3d4dd61
Autor:
E I Chazov, N Iu Mironov, Sergey P. Golitsyn, Maĭkov Eb, Iu A Iuricheva, Rozenshtraukh Lv, S. F. Sokolov
Publikováno v:
Kardiologiia. 54(1)
This article reviews experimental and clinical studies of a novel antiarrhythmic agent niferidile. Niferidile, a class III antiarrhythmic agent, blocks potassium outward currents, prolongs repolarization and refractory periods predominantly in atria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a72d9bd23f6e7a8a1839923e75f279
https://pubmed.ncbi.nlm.nih.gov/24881306
https://pubmed.ncbi.nlm.nih.gov/24881306
Autor:
Iu V, Mareev, V N, Shitov, V G, Kiktev, O V, Sapel'nikov, R S, Latypov, I R, Grishin, T A, Malkina, L Iu, Nesterenko, Iu A, Iuricheva, S F, Sokolov, M A, Saidova, R S, Akchurin, S P, Golitsyn
Publikováno v:
Kardiologiia. 53(5)
In our study we compared effect of cardiac resynchronization therapy (CRT) in chronic heart failure (CHF) patients with permanent atrial fibrillation (AF) and patients with sinus rhythm. Special feature of our work was that patients with permanent at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::916073bc246838c25c6e6a789e5a62eb
https://pubmed.ncbi.nlm.nih.gov/23952994
https://pubmed.ncbi.nlm.nih.gov/23952994
Autor:
N Iu, Mironov, S P, Golitsyn, S F, Sokolov, E B, Maĭkov, N B, Shlevkov, Iu A, Iuricheva, Iu V, Mareev, L V, Rosenshtraukh, E I, Chazov
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 75(10)
Intracardiac electrophysiological effects and antiarrhythmic activity of novel domestic class III antiarrhythmogenic drug niferidil has been studied in a group of 25 patients with paroxismal supraventricular tachycardia (PSVT) diagnosis. The drug was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bc71560e7881b7b5961817a55e7ee410
https://pubmed.ncbi.nlm.nih.gov/23240154
https://pubmed.ncbi.nlm.nih.gov/23240154
Autor:
Iu A, Iuricheva, E B, Maĭkov, S F, Sokolov, Iu L, Klimenko, T L, Kratskina, G S, Tarasovskiĭ, O A, Bil'dinov, S A, Bakalov, S P, Golitsyn, G G, Beloshapko, A V, Iushmanova, L V, Rozenshtraukh, E I, Chazov
Publikováno v:
Kardiologiia. 51(1)
The aim of the study was to evaluate the efficacy and safety of administered intravenously niferidil in doses 10, 20 and 30 mkg per kg in patients with persistent atrial fibrillation (AF) and flutter (AFL) for pharmacological cardioversion. The study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::69582e54b6477f1031d8ce65fa7e82d7
https://pubmed.ncbi.nlm.nih.gov/21626804
https://pubmed.ncbi.nlm.nih.gov/21626804